LivaNova's stock price target was raised to $85 following a strong Q2 performance with record revenue of $390.6 million, up 9.8%, and adjusted EPS of $1.26, beating estimates by 16.67%. The growth was driven by its Cardiopulmonary and Epilepsy segments. The company also raised its full-year revenue and EPS outlook but lowered free cash flow forecasts due to increased investments in manufacturing and innovation, positioning it for future growth.
Needham reaffirmed its 'Buy' rating for Viasat, highlighting strong growth in its Defense and Advanced Technologies division, which boosted the company's backlog to $1.4 billion. Despite slightly missing revenue estimates, Viasat exceeded earnings pe...
Arbor Realty Trust reported a GAAP net loss of $37.3 million in Q2 2026, driven by higher credit provisions and lower interest income. Despite the loss, distributable earnings were $0.10 per share, below the $0.17 quarterly dividend, which was reduce...
Leggett & Platt is set to release its quarterly earnings on August 6, 2026, with analysts expecting an EPS of $0.26 and revenue near $983 million. The company shows a low P/E ratio of 6.33 and a P/S ratio of 0.35, indicating a potentially undervalued...
Suja Life's stock fell sharply by 46.18% following a 391% rise in net loss and a securities law investigation, closing at $6.14 on heavy volume. Other companies like Autonomix Medical, Limbach Holdings, USANA Health Sciences, and SolarEdge Technologi...
Transocean Ltd. announced new offshore drilling contracts worth approximately $292 million in firm fixtures and an additional $1.0 billion conditional agreement with Equinor for rigs on the Norwegian shelf. These contracts extend drilling programs ac...
